Are endocannabinoid type 1 receptor gene (CNR1) polymorphisms associated with obesity and metabolic syndrome in postmenopausal Polish women

International Journal of Obesity

Volumn 35, Issue 3, 2011, Pages 373-377

  Milewicz, A ^a   Tworowska Bardzinska U ^a   Jedrzejuk D ^a   Lwow, F ^b   Dunajska, K ^b   Laczmanski L ^a   Pawlak, M ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b UNIVERSITY SCHOOL OF PHYSICAL EDUCATION   (Poland)

Author keywords

CNR1 polymorphism; metabolic syndrome; postmenopausal women

Indexed keywords

CANNABINOID 1 RECEPTOR; ENDOCANNABINOID; GLUCOSE; INSULIN; LIPID;

ADULT; ALLELE; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY FAT DISTRIBUTION; BODY MASS; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; OBESITY; PHARMACOGENETICS; POSTMENOPAUSE; PRIORITY JOURNAL; RECEPTOR GENE; SINGLE NUCLEOTIDE POLYMORPHISM; WAIST CIRCUMFERENCE;

ADIPOSITY; BODY FAT DISTRIBUTION; BODY MASS INDEX; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; POLAND; POLYMORPHISM, GENETIC; POSTMENOPAUSE; RECEPTOR, CANNABINOID, CB1;

EID: 79952698829     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2010.145     Document Type: Article

References (21)

1. Milewicz A, Tworowska U, Demissie M. Menopausal obesity -myth or fact? Climacteric 2001; 4: 273-283.
2. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004; 3: 771-784. (Pubitemid 39242829)
3. Pagotto U, Vicennati V, Pasquali R. The endocannabinoid system and the treatment of obesity. Ann Med 2005; 37: 270-275. (Pubitemid 40911063)
4. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005; 8: 585-589. (Pubitemid 40594198)
5. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006; 27: 73-100. (Pubitemid 43228239)
6. Osei-Hyiaman D, Harvey-White J, Batkai S, Kunos G. The role of the endocannabinoid system in the control of energy homeo-stasis. Int J Obes 2006; 30: S33-S38.
7. Zhang PW, Ishiguro H, Ohtsuki T, Hess J, Carillo F, Walther D et al. Human cannabinoid receptor 1:5-exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. Mol Psychiatry 2004; 9: 916-931.
8. Russo P, Strazzullo P, Cappuccio FP, Tregouet DA, Lauria F, Loguercio M et al. Genetic variations at the endocannabinoid type 1 receptor gene (CNR1) are associated with obesity pheno-types in men. J Clin Endocrinol Metab 2007; 92: 2382-2386. (Pubitemid 46997151)
9. Peeters A, Beckers S, Mertens I, Van Hul W, Van Gaal L. The G1422A variant of the cannabinoid receptor gene (CNR1) is associated with abdominal adiposity in obese men. Endocrine 2007; 31: 138-141. (Pubitemid 350195147)
10. Benzinou M, Chévre JC, Ward KJ, Lecoeur C, Dina C, Lobbens S et al. Endocannabinoid receptor 1 gene variations increase risk for obesity and modulate body mass index in European populations. Hum Mol Genet 2008; 17: 1916-1921. (Pubitemid 351865840)
11. Greenfield JR, Samaras K, Chisholm DJ. Insulin resistance, intra-abdominal fat, cardiovascular risk factors, and androgens in healthy young women with type 1 diabetes mellitus. J Clin Endocrinol Metab 2002; 87: 1036-1040. (Pubitemid 36121061)
12. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. End Rev 2000; 21: 637-738.
13. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S, RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-1397. (Pubitemid 40523733)
14. Despres JP, Golay A, Sjostrom L, Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121-2134. (Pubitemid 41653104)
15. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006; 295: 761-775. (Pubitemid 43244304)
16. Jaeger JP, Mattevi VS, Callegari-Jacques SM, Hutz MH. Cannabi-noid type-1 receptor gene polymorphisms are associated with central obesity in a Southern Brazilian population. Dis Markers 2008; 25: 67-74.
17. Gazzerro P, Caruso MG, Notarnicola M, Misciagna G, Guerra V, Laezza C et al. Association between cannabinoid type-1 receptor polymorphism and body mass index in a southern Italian population. Int J Obes (Lond) 2007; 31: 908-912. (Pubitemid 46842680)
18. Lieb W, Manning AK, Florez JC, Dupuis J, Cupples LA, McAteer JB et al. Variants in the CNR1 and the FAAH genes and adiposity traits in the community. Obesity 2009; 17: 755-760.
19. Siani A, Strazzullo P. Tackling the genetic bases of metabolic syndrome: a realistic objective? Nutr Metab Cardiovasc Dis 2006; 5: 309-312. (Pubitemid 43994437)
20. Blakemore AIF, Froguel P. Is obesity our genetic legacy? J Clin Endocrinol Metab 2008; 93: S51-S56.
21. Aberle J, Flitsch J, Beck NA, Mann O, Busch P, Peitsmeier P et al. Genetic variation may influence obesity only under conditions of diet: analysis of three candidate genes. Mol Genet Metab 2008; 95: 188-191.